Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome

被引：15

作者：

Ganzel, Chezi ^{[1
]}

Rouvio, Ory ^{[2
]}

Avivi, Irit ^{[3
]}

Magen, Hila ^{[4
]}

Jarchowsky, Osnat ^{[5
]}

Herzog, Katrin ^{[6
]}

Cohen, Yossi ^{[7
]}

Tadmor, Tamar ^{[8
]}

Horwitz, Netanel A. ^{[9
]}

Leiba, Merav ^{[10
]}

Nagler, Arnon ^{[10
]}

Cohen, Yael ^{[3
]}

Bulvik, Shlomo ^{[6
]}

Polliack, Aaron ^{[11
]}

Rowe, Jacob M. ^{[1
]}

Gatt, Moshe E. ^{[11
]}

机构：

[1] Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel

[2] Soroka Univ Med Ctr, Dept Hematol, Negev Beer Sheva, Israel

[3] Sorasky Med Ctr, Dept Hematol, Tel Aviv, Israel

[4] Rabin Med Ctr, Inst Hematol, Petah Tiqwa, Israel

[5] Meir Med Ctr, Dept Hematol, Kefar Sava, Israel

[6] Assaf Harofeh Med Ctr, Dept Hematol, Zerifin, Israel

[7] Laniado Med Ctr, Dept Hematol, Netanya, Israel

[8] Bnai Zion Med Ctr, Hematol Unit, Haifa, Israel

[9] Rambam Healthcare Campus, Dept Hematol, Haifa, Israel

[10] Chaim Sheba Med Ctr, Div Hematol & Bone Marrow Transplantat, Ramat Gan, Israel

[11] Hadassah Med Ctr, Dept Hematol, Jerusalem, Israel

来源：

LEUKEMIA RESEARCH | 2018年 / 68卷

关键词：

Primary plasma cell leukemia; Multiple myeloma; Novel agents; Immunomodulatory drugs (IMiDs); MULTIPLE-MYELOMA; RESPONSE CRITERIA; SINGLE-CENTER; SURVIVAL; TRANSPLANTATION; DEXAMETHASONE; BORTEZOMIB; EXPERIENCE; IMPROVES; THERAPY;

D O I：

10.1016/j.leukres.2018.02.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Primary plasma cell leukemia (PPCL) is a rare form of multiple myeloma with a dismal prognosis. This retrospective multi-center study examines the national experience of PPCL in the era of novel agents. During 2002-2016, thirty-nine patients with PPCL were identified in 11 Israeli centers. One-fifth of them died in the first 2 months after diagnosis. The overall survival (OS) of those who survived the first 3 months was 22.5 months. About 70% of patients received at least one type of immunomodulatory drug (IMiD) and similarly proteasome inhibitor (PI) during treatment. There was a survival advantage for those who received IMiD but not for those who received PI or other type of standard dose chemotherapy. In multivariate analysis, low performance status and increased uric acid were also associated with shorter OS. In conclusion, this study demonstrates favorable impact of treatment with IMiDs and hematopoietic cell transplantation on the survival of PPCL patients.

引用

页码：9 / 14

页数：6

共 28 条

[1] Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience
Avet-Loiseau, H.
Roussel, M.
Campion, L.
Leleu, X.
Marit, G.
Jardel, H.
Dib, M.
Decaux, O.
Lamy, T.
Tiab, M.
Cony-Makhoul, P.
Banos, A.
Lepeu, G.
Lifermann, F.
Macro, M.
Kolb, B.
Hulin, C.
Caillot, D.
Traulle, C.
Mathiot, C.
Royer, B.
[J]. LEUKEMIA, 2012, 26 (01) : 158 - 159
[2] Thirty patients with primary plasma cell leukemia: a single center experience
Colovic, Milica
Jankovic, Gradimir
Suvajdzic, Nada
Milic, Natasa
Dordevic, Vesna
Jankovic, Snezana
[J]. MEDICAL ONCOLOGY, 2008, 25 (02) : 154 - 160
[3] Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party
D'Arena, G.
Valentini, C. G.
Pietrantuono, G.
Guariglia, R.
Martorelli, M. C.
Mansueto, G.
Villani, O.
Onofrillo, D.
Falcone, A.
Specchia, G.
Semenzato, G.
Di Renzo, N.
Mastrullo, L.
Venditti, A.
Ferrara, F.
Palumbo, A.
Pagano, L.
Musto, P.
[J]. ANNALS OF ONCOLOGY, 2012, 23 (06) : 1499 - 1502
[4] PRIMARY PLASMA-CELL LEUKEMIA
DIMOPOULOS, MA
PALUMBO, A
DELASALLE, KB
ALEXANIAN, R
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (04) : 754 - 759
[5] Primary plasma cell leukemia and autologous stem cell transplantation
Drake, Mary B.
Iacobelli, Simona
van Biezen, Anja
Morris, Curly
Apperley, Jane F.
Niederwieser, Dietger
Bjorkstrand, Bo
Gahrton, Gosta
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (05): : 804 - 809
[6] International uniform response criteria for multiple myeloma
Durie, B. G. M.
Harousseau, J-L
Miguel, J. S.
Blade, J.
Barlogie, B.
Anderson, K.
Gertz, M.
Dimopoulos, M.
Westin, J.
Sonneveld, P.
Ludwig, H.
Gahrton, G.
Beksac, M.
Crowley, J.
Belch, A.
Boccadaro, M.
Turesson, I.
Joshua, D.
Vesole, D.
Kyle, R.
Alexanian, R.
Tricot, G.
Attal, M.
Merlini, G.
Powles, R.
Richardson, P.
Shimizu, K.
Tosi, P.
Morgan, G.
Rajkumar, S. V.
[J]. LEUKEMIA, 2006, 20 (09) : 1467 - 1473
[7] Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
Fernandez de Larrea, C.
Kyle, R. A.
Durie, B. G. M.
Ludwig, H.
Usmani, S.
Vesole, D. H.
Hajek, R.
San Miguel, J. F.
Sezer, O.
Sonneveld, P.
Kumar, S. K.
Mahindra, A.
Comenzo, R.
Palumbo, A.
Mazumber, A.
Anderson, K. C.
Richardson, P. G.
Badros, A. Z.
Caers, J.
Cavo, M.
Leleu, X.
Dimopoulos, M. A.
Chim, C. S.
Schots, R.
Noeul, A.
Fantl, D.
Mellqvist, U-H
Landgren, O.
Chanan-Khan, A.
Moreau, P.
Fonseca, R.
Merlini, G.
Lahuerta, J. J.
Blade, J.
Orlowski, R. Z.
Shah, J. J.
[J]. LEUKEMIA, 2013, 27 (04) : 780 - 791
[8] Primary plasma cell leukemia:: Clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics
García-Sanz, R
Orfao, A
González, M
Tabernero, MD
Bladé, J
Moro, MJ
Fernández-Calvo, J
Sanz, MA
Pérez-Simón, JA
Rasillo, A
San Miguel, JF
[J]. BLOOD, 1999, 93 (03) : 1032 - 1037
[9] Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)
Gonsalves, Wilson I.
Buadi, Francis K.
Kumar, Shaji K.
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (02) : 215 - 217
[10] Trends in survival of patients with primary plasma cell leukemia: a population-based analysis
Gonsalves, Wilson I.
Rajkumar, S. Vincent
Go, Ronald S.
Dispenzieri, Angela
Gupta, Vinay
Singh, Preet P.
Buadi, Francis K.
Lacy, Martha Q.
Kapoor, Prashant
Dingli, David
Lust, John A.
Zeldenrust, Steven R.
Hayman, Suzanne R.
Kyle, Robert A.
Gertz, Morie A.
Kumar, Shaji K.
[J]. BLOOD, 2014, 124 (06) : 907 - 912

← 1 2 3 →